A Phase 2a clinical trial was completed with positive results in IPF patients with chronic cough, an orphan disease with no curative therapy, and a robust Phase 2b study has been initiated for this often-debilitating condition. The company is led by experienced respiratory drug developers with prior exits including Elevation Pharmaceuticals (acquired 2012) and Patara Pharma. However, Respivant is a deadpooled company and is not active anymore.
Cyborg Score Rationale
The company has been shutdown/deadpooled despite having promising Phase 2b clinical data in a well-defined orphan indication (IPF chronic cough). The experienced management team with prior successful exits could not sustain operations or secure continued funding.
Top Insights
Acquired RVT-1601 from Patara Pharma in September 2018 along with founder/executive team (Bill Gerhart, Ahmet Tutuncu, Pravin Soni)
Lead asset showed statistically significant cough reduction in Phase 2a IPF trials; Phase 2b (SCENIC trial) initiated in May 2019
Subsidiary structure under Roivant Sciences umbrella limited operational independence and likely tied funding to parent company dynamics
Orphan disease focus (IPF cough) offers regulatory incentives but limited commercial addressable market; company unable to achieve profitability or product approval
Named Competitors
aTyr Pharma — Respiratory and immunology therapeutic developer
ReCode Therapeutics — Gene therapy for respiratory diseases
Lonhala Magnair — LAMA inhaled therapy for COPD
Recent Developments
(September 2018) Company launched as Roivant Sciences subsidiary
(May 2019) First patient dosed in Phase 2b SCENIC trial for RVT-1601
(2025) Company marked as deadpooled; operations appear to have ceased
Open the full interactive Respivant Sciences report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.